Abstract
Artemether-Lumefantrine (AL) and Artesunate-Amodiaquine (ASAQ) are recommended for the treatment of uncomplicated malaria in Chad. The objective of this study was to evaluate the High efficacy of Artemether–Lumefantrine and Artesunate-Amodiaquine for the treatment of uncomplicated falciparum malaria in Massokory, Mondo and Dourbali provinces (Chad).The study was carried out in 2019, 1113 patients children aged from 6 to 60 months were randomly assigned treatment with Artemether-Lumefantrine and Artesunate-Amodiaquine and followed up for 28 days. Primary endpoint was the treatment efficacy over 28 days. The early treatment failure was (0.13%) in AL group and (0.17%) in ASAQ group. No early clinical failure was found. Adequate clinical and parasitological responses were significantly higher in Artesunate-Amodiaquine group (ASAQ) (99.82% versus (99.10%) in Artemether-Lumefantrine (AL) group, p = 0.0009). All treatments had a similar and good tolerability profile that confirm the high efficacy of the first- and the newly recommended alternative ACT for treatments for uncomplicated falciparum malaria in Chad. The high parasite density clearance suggests absence of suspected artemisinin resistance, defined as delayed parasite clearance  
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of Biomedical Engineering and Medical Imaging
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
